|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000025961 |
|
Date of registration:
|
01/03/2017 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
The study of effect of Alfacalcidol treatment on Crohn's disease
|
|
Scientific title:
|
The study of effect of Alfacalcidol treatment on Crohn's disease - The study of effect of Alfacalcidol treatment on Crohn's disease |
|
Date of first enrolment:
|
2017/05/21 |
|
Target sample size:
|
31 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029845 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
Tsunaki
Sawada |
|
Address:
|
65 Tsurumai, Shouwa, Nagoya-City, Aichi
466-8560
Japan |
|
Telephone:
|
0527442172 |
|
Email:
|
t.sawada@med.nagoya-u.ac.jp |
|
Affiliation:
|
Nagoya University Hospital Department of Gastroenterology and Hepatology |
|
|
Name:
|
Masanao
Nakamura |
|
Address:
|
65 Tsurumai, Shouwa, Nagoya-City, Aichi
Japan |
|
Telephone:
|
0527442172 |
|
Email:
|
osa-wata@med.nagoya-u.ac.jp |
|
Affiliation:
|
Nagoya University Hospital Department of Gastroenterology and Hepatology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: Patient who has moderate to severe colitis Hypercalcemia Patient who is taking Calcium formulation,Vitamin D and Vitamin D analog Patient who is taking medicine including magnesium, digitalis, PTH formulation. Expectant and nursing mothers
Age minimum:
18years-old
Age maximum:
Not applicable
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Crohn's disease
|
|
Intervention(s)
|
|
Oral treatment of Alfacalcidol 1 microgram/day for 3 month
|
|
Primary Outcome(s)
|
|
Improvement rate on endoscopic score after 3 month.
|
|
Secondary Outcome(s)
|
|
Improvement rate on clinical score comparison of endoscopic score, clinical score, biomarker between before and after treatment
|
|
Source(s) of Monetary Support
|
|
Nagoya University Graduate School of Medicine
|
|
Ethics review
|
Status: YES
Approval date: 21/05/2017
Contact:
ethics@med.nagoya-u.ac.jp
Nagoya University Certified Review Board
052-744-2479
ethics@med.nagoya-u.ac.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
31/03/2020 |
|
URL:
|
|
|
|